Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Scott

Showing results (41-50 of 159) with videos related to

Pageof 16
Sort By:
Addiction (Abingdon, England)|November 18, 2021
The cost and impact of distributing naloxone to people who are prescribed opioids to prevent opioid-related deaths: findings from a modelling studySuzanne Nielsen, Nick Scott, Tom Tidhar, et al.
Open Forum Infectious Diseases|September 22, 2025
Cost-effectiveness of Alternative Approaches to Hepatitis C Diagnosis and Treatment Initiation for Treatment-naive People Who Inject Drugs in Australia: A Model-based Economic EvaluationChristopher R Bailie, Nick Scott, Alisa E Pedrana, et al.
Journal of Viral Hepatitis|October 23, 2024
Cost-Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in AustraliaJoshua F Ginnane, Nick Scott, Andrew Radley, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|September 25, 2020
Cost-effectiveness of uterine tamponade devices for the treatment of postpartum hemorrhage: A systematic reviewJoshua P Vogel, Alyce N Wilson, Nick Scott, et al.
The Lancet. Gastroenterology & Hepatology|July 30, 2023
A global investment case for hepatitis B elimination: a modelling studyChristopher P Seaman, Phillip Luong, Yinzong Xiao, et al.
BMC Medicine|August 21, 2015
The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatmentsNick Scott, Emma McBryde, Peter Vickerman, et al.
The Lancet. Global Health|May 19, 2018
Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling studyNick Scott, Anna Palmer, Christopher Morgan, et al.
The Medical Journal of Australia|November 24, 2020
Impact of Victoria's Stage 3 lockdown on COVID-19 case numbersAllan Saul, Nick Scott, Brendan S Crabb, et al.
Journal of Virus Eradication|April 24, 2018
Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment accessNick Scott, Samuel W Hainsworth, Rachel Sacks-Davis, et al.
AIDS (London, England)|September 15, 2025
Evaluating the impact of COVID-19 on the HIV epidemic among MSM in AustraliaRongxing Weng, Jisoo A Kwon, Mo Hammoud, et al.
Pageof 16

Showing results (41-50 of 159) with videos related to

Sort By:
Pageof 16
Addiction (Abingdon, England)|November 18, 2021
The cost and impact of distributing naloxone to people who are prescribed opioids to prevent opioid-related deaths: findings from a modelling studySuzanne Nielsen, Nick Scott, Tom Tidhar, et al.
Open Forum Infectious Diseases|September 22, 2025
Cost-effectiveness of Alternative Approaches to Hepatitis C Diagnosis and Treatment Initiation for Treatment-naive People Who Inject Drugs in Australia: A Model-based Economic EvaluationChristopher R Bailie, Nick Scott, Alisa E Pedrana, et al.
Journal of Viral Hepatitis|October 23, 2024
Cost-Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in AustraliaJoshua F Ginnane, Nick Scott, Andrew Radley, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|September 25, 2020
Cost-effectiveness of uterine tamponade devices for the treatment of postpartum hemorrhage: A systematic reviewJoshua P Vogel, Alyce N Wilson, Nick Scott, et al.
The Lancet. Gastroenterology & Hepatology|July 30, 2023
A global investment case for hepatitis B elimination: a modelling studyChristopher P Seaman, Phillip Luong, Yinzong Xiao, et al.
BMC Medicine|August 21, 2015
The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatmentsNick Scott, Emma McBryde, Peter Vickerman, et al.
The Lancet. Global Health|May 19, 2018
Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling studyNick Scott, Anna Palmer, Christopher Morgan, et al.
The Medical Journal of Australia|November 24, 2020
Impact of Victoria's Stage 3 lockdown on COVID-19 case numbersAllan Saul, Nick Scott, Brendan S Crabb, et al.
Journal of Virus Eradication|April 24, 2018
Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment accessNick Scott, Samuel W Hainsworth, Rachel Sacks-Davis, et al.
AIDS (London, England)|September 15, 2025
Evaluating the impact of COVID-19 on the HIV epidemic among MSM in AustraliaRongxing Weng, Jisoo A Kwon, Mo Hammoud, et al.
Pageof 16